Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experience

Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experience

Abstract Background This study aims to evaluate the cost-effectiveness of Trastuzumab deruxtecan (T-DXd), compared to trastuzumab emtansine (T-DM1) as second-line treatments for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) patients in Iran. Methods A partit...

Full description

Saved in:
Bibliographic Details
Main Authors: Neda Yaghoubi, Behzad Fatemi, Razieh Ahmadi, Yalda Metghalchi, Bita Shahrami, Mohammad Vaezi, Soheila Rezaei
Format: Article
Language:English
Published: BMC 2025-05-01
Series:BMC Health Services Research
Subjects:
Breast cancer
Cost-effectiveness
HER2-positive metastatic breast cancer
Price exploration
Targeted therapy
Online Access:https://doi.org/10.1186/s12913-025-12876-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12913-025-12876-6

Similar Items